Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Galecto, Inc. (DMRA : NSDQ)

• Company Description    Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on galectin-3 and LOXL2. The Company's pipeline includes an inhaled galectin-3 modulator currently in Phase 2b for the potential treatment of idiopathic pulmonary fibrosis. Galecto Inc. is headquarters in Copenhagen, Denmark. Number of Employees: 7

• Price / Volume Information    Yesterday's Closing Price: $25.09 Daily Weekly Monthly 20 Day Moving Average: 292,708 shares Shares Outstanding: 60.30 (millions) Market Capitalization: $1,513.01 (millions) Beta: 1.59 52 Week High: $38.33 52 Week Low: $2.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.21% -11.14% 12 Week 22.39% 29.52% Year To Date 9.04% 13.39%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 221 Crescent Street Building 23 Suite 105 - Boston,MA 02109 DNK ph: 781-281-9020 fax: - investors@damoratx.com http://www.galecto.com

• General Corporate Information    Officers Carl Goldfischer - Chairman Sherwin Sattarzadeh - Chief Operating Officer Lori Firmani - Chief Financial Officer Julianne Bruno - Director Jayson Dallas - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 36322Q206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 05/14/26 Share - Related Items Shares Outstanding: 60.30 Most Recent Split Date: 8.00 (0.04:1) Beta: 1.59 Market Capitalization: $1,513.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.95 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 30.38% vs. Previous Quarter: 9.23% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - -147.05 ROA 03/31/26 - - 12/31/25 - -279.49 09/30/25 - -111.33 Current Ratio 03/31/26 - - 12/31/25 - 12.98 09/30/25 - 3.73 Quick Ratio 03/31/26 - - 12/31/25 - 12.98 09/30/25 - 3.73 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - - 12/31/25 - -110.11 09/30/25 - 5.03 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - - 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©